Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to -$10.4 million.

  • Anaptysbio's Cash from Financing Activities fell 11458.8% to -$10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.9 million, marking a year-over-year decrease of 16563.48%. This contributed to the annual value of $127.1 million for FY2024, which is 31426.72% up from last year.
  • Per Anaptysbio's latest filing, its Cash from Financing Activities stood at -$10.4 million for Q3 2025, which was down 11458.8% from -$50.5 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Cash from Financing Activities ranged from a high of $251.3 million in Q4 2021 and a low of -$50.5 million during Q2 2025
  • Moreover, its 5-year median value for Cash from Financing Activities was $241000.0 (2021), whereas its average is $14.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 19937301.59% in 2021, then tumbled by 322314.81% in 2023.
  • Anaptysbio's Cash from Financing Activities (Quarter) stood at $251.3 million in 2021, then crashed by 99.22% to $1.9 million in 2022, then crashed by 364.7% to -$5.2 million in 2023, then skyrocketed by 634.35% to $27.6 million in 2024, then tumbled by 137.69% to -$10.4 million in 2025.
  • Its Cash from Financing Activities was -$10.4 million in Q3 2025, compared to -$50.5 million in Q2 2025 and -$28.6 million in Q1 2025.